A randomized double-blind controlled exploratory study comparing CS-8958 to oseltamivir phosphate in patients with influenza virus infection (Phase 2)
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Laninamivir (Primary) ; Oseltamivir
- Indications Influenza virus infections
- Focus Therapeutic Use
- Sponsors Biota Holdings; Daiichi Sankyo Company
- 31 Jul 2008 Active comparator identified as oseltamivir in a Biota Holdings media release.
- 31 Jul 2008 Status changed from unconfirmed to completed, as reported by Biota Holdings.
- 20 Dec 2007 New trial record.